Bioneeds is dedicated to provide end-to-end Biologics Drug Development Services with its two distinct technology platforms:
Capabilities include development of recombinant proteins such as non-glycosylated proteins; glycoproteins and monoclonal antibodies derived from either bacterial or mammalian host expression systems.
Our Preclinical platform is supported by OECD-GLP and AAALAC certified animal facilities.
We have the expertise to handle Novel Biologics, Biosimilars and Biobetters.
RCGM; EMEA; US-FDA
Method Development; Validation;
Animal Studies; Sample Analysis
Antibody Generation; Screening Assays; Confirmatory Assays; Neutralizing Antibody Assays
HCP; HCD; Others
Immunization; Purification; Characterization; Reactivity
Codon Optimization; Clone Stability; Bioreactor Suitability; Titre ; Product Quality
Cell Culture & Purification ; Critical Process Parameters; COGS
Analytical; Bio / Analytical; Potency (Compliance to Standard Guidelines and Pharmacopeia)
Compliance to Standard Guidelines and Pharmacopeia
Complete Product Development (starting with sequence) with tox material supply